Shield Therapeutics is a well-funded, high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.
Shield has a rare opportunity to build an integrated, highly profitable specialty pharma business. In this section you can learn more about our lead product, and about our second asset.
Shield is well positioned to become a fast growing, independent, international specialty pharmaceutical company due to the strength of its products and team, and with great thanks to all of our supportive shareholders.
1 Oct 2018
Shield Therapeutics plc, today announces that it has received confirmation from the US FDA of its successful submission of an NDA for Feraccru®. For more details please see the press release below.